Financial News

Financial Report: Roche

Pharmaceutical sales up 12% in the quarter driven by Ocrevus, Perjeta and Tecentriq, and new haemophilia drug Hemlibra

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche 1Q Revenues: 14.8 billion CHF (+9%) Comments: Pharmaceutical sales were 11.9 billion CHF, up 12%. Key growth drivers were multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra, partially offset by lower sales of Herceptin and of MabThera/Rituxan. In the U.S., sales increased 14%, led by Ocrevus, Hemlibra, Perjeta and Tecentriq. In Europe sales were down 6% affected by competition from biosimilars for Herceptin (dow...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters